SCHEMBL4983383

SCHEMBL4983383

Cc1ccc(N(C(=O)OC(C)(C)C)c2nc3cc(Nc4ccnc(Cl)n4)ccc3n2C)cc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
BRAF P15056 9/20 0.36
SYK P43405 1/20 0.35
AGPAT2 O15120 1/20 0.35
MAPK14 Q16539 1/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
RAF1 P04049 2/20 0.34
LCK P06239 1/20 0.34
FYN P06241 1/20 0.34
PDGFRB P09619 1/20 0.34
KIT P10721 1/20 0.34
SRC P12931 1/20 0.34
FLT1 P17948 1/20 0.34
FLT4 P35916 1/20 0.34
KDR P35968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4978728 0.92 BRAF (0.37) NPC1RAB9ABRAFSYKMAPK14
SCHEMBL4983374 0.92 BRAF (0.44) NPC1RAB9ABRAFSYKRAF1
SCHEMBL4980380 0.92 BRAF (0.37) NPC1RAB9ABRAFSYKPOLB
SCHEMBL4980603 0.92 BRAF (0.39) NPC1RAB9ABRAFMAPK14KDM4E
SCHEMBL5228478 0.88 NPC1 (0.41) NPC1RAB9ABRAFAGPAT2MAPK14
SCHEMBL4976646 0.84 KDR (0.37) NPC1RAB9ABRAFSYKAGPAT2
SCHEMBL14263381 0.83 BRAF (0.36) BRAFSYKMAPK14KDM4ERAF1
SCHEMBL5226236 0.82 BRAF (0.45) NPC1RAB9ABRAFKDM4EPOLB
SCHEMBL5230055 0.80 BRAF (0.39) NPC1RAB9ABRAFKDM4EMAPT
SCHEMBL4978634 0.80 BRAF (0.37) NPC1RAB9ABRAFSYKKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7338959-B2 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US disclosed
US-7338959-B2 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US disclosed
US-7338959-B2 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US disclosed
US-20050234083-A1 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234083-A1 Diamino-pyrimidines and their use as angiogenesis inhibitors TIE1, TEK, KDR NPC1 4748/4885RAB9A 4360/4885BRAF 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.